Logo image of PRCT

PROCEPT BIOROBOTICS CORP (PRCT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRCT - US74276L1052 - Common Stock

34.71 USD
+1.59 (+4.8%)
Last: 1/6/2026, 8:00:01 PM
33.59 USD
-1.12 (-3.23%)
After Hours: 1/6/2026, 8:00:01 PM
Fundamental Rating

4

PRCT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. PRCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRCT is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PRCT had negative earnings in the past year.
In the past year PRCT has reported a negative cash flow from operations.
PRCT had negative earnings in each of the past 5 years.
In the past 5 years PRCT always reported negative operating cash flow.
PRCT Yearly Net Income VS EBIT VS OCF VS FCFPRCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

PRCT has a Return On Assets (-16.53%) which is in line with its industry peers.
PRCT has a better Return On Equity (-22.24%) than 60.54% of its industry peers.
Industry RankSector Rank
ROA -16.53%
ROE -22.24%
ROIC N/A
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
PRCT Yearly ROA, ROE, ROICPRCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

PRCT has a better Gross Margin (64.55%) than 68.11% of its industry peers.
In the last couple of years the Gross Margin of PRCT has grown nicely.
The Profit Margin and Operating Margin are not available for PRCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
PRCT Yearly Profit, Operating, Gross MarginsPRCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

PRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRCT has more shares outstanding
Compared to 5 years ago, PRCT has more shares outstanding
Compared to 1 year ago, PRCT has an improved debt to assets ratio.
PRCT Yearly Shares OutstandingPRCT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRCT Yearly Total Debt VS Total AssetsPRCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

PRCT has an Altman-Z score of 7.72. This indicates that PRCT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PRCT (7.72) is better than 86.49% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that PRCT is not too dependend on debt financing.
The Debt to Equity ratio of PRCT (0.14) is better than 62.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 7.72
ROIC/WACCN/A
WACC9.82%
PRCT Yearly LT Debt VS Equity VS FCFPRCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 8.44 indicates that PRCT has no problem at all paying its short term obligations.
PRCT's Current ratio of 8.44 is amongst the best of the industry. PRCT outperforms 89.19% of its industry peers.
PRCT has a Quick Ratio of 7.20. This indicates that PRCT is financially healthy and has no problem in meeting its short term obligations.
PRCT has a Quick ratio of 7.20. This is amongst the best in the industry. PRCT outperforms 89.19% of its industry peers.
Industry RankSector Rank
Current Ratio 8.44
Quick Ratio 7.2
PRCT Yearly Current Assets VS Current LiabilitesPRCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.54% over the past year.
Looking at the last year, PRCT shows a very strong growth in Revenue. The Revenue has grown by 50.07%.
The Revenue has been growing by 105.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
Revenue 1Y (TTM)50.07%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%42.76%

3.2 Future

Based on estimates for the next years, PRCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.88% on average per year.
PRCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.01% yearly.
EPS Next Y12.5%
EPS Next 2Y15.69%
EPS Next 3Y18%
EPS Next 5Y15.88%
Revenue Next Year46.32%
Revenue Next 2Y37.63%
Revenue Next 3Y33.25%
Revenue Next 5Y26.01%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PRCT Yearly Revenue VS EstimatesPRCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
PRCT Yearly EPS VS EstimatesPRCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRCT Price Earnings VS Forward Price EarningsPRCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRCT Per share dataPRCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PRCT's earnings are expected to grow with 18.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.69%
EPS Next 3Y18%

More info and screens

0

5. Dividend

5.1 Amount

PRCT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PROCEPT BIOROBOTICS CORP

NASDAQ:PRCT (1/6/2026, 8:00:01 PM)

After market: 33.59 -1.12 (-3.23%)

34.71

+1.59 (+4.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-23 2026-02-23/amc
Inst Owners106.65%
Inst Owner Change0%
Ins Owners4.23%
Ins Owner Change13.22%
Market Cap1.94B
Revenue(TTM)299.91M
Net Income(TTM)-84.58M
Analysts84.21
Price Target53.81 (55.03%)
Short Float %11.39%
Short Ratio4.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.37%
Min EPS beat(2)9.47%
Max EPS beat(2)17.27%
EPS beat(4)3
Avg EPS beat(4)8.01%
Min EPS beat(4)-4.69%
Max EPS beat(4)17.27%
EPS beat(8)6
Avg EPS beat(8)5.92%
EPS beat(12)8
Avg EPS beat(12)3.91%
EPS beat(16)10
Avg EPS beat(16)4.32%
Revenue beat(2)2
Avg Revenue beat(2)1.27%
Min Revenue beat(2)0.93%
Max Revenue beat(2)1.61%
Revenue beat(4)4
Avg Revenue beat(4)1.49%
Min Revenue beat(4)0.18%
Max Revenue beat(4)3.23%
Revenue beat(8)8
Avg Revenue beat(8)3.05%
Revenue beat(12)11
Avg Revenue beat(12)2.51%
Revenue beat(16)15
Avg Revenue beat(16)5.35%
PT rev (1m)-2.64%
PT rev (3m)-20.62%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)-21.11%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)-1.64%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-2.32%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.47
P/FCF N/A
P/OCF N/A
P/B 5.1
P/tB 5.11
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.43
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS5.37
BVpS6.81
TBVpS6.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.53%
ROE -22.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.55%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 141.51%
Cap/Sales 2.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.44
Quick Ratio 7.2
Altman-Z 7.72
F-Score6
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)279.88%
Cap/Depr(5y)173.09%
Cap/Sales(3y)8%
Cap/Sales(5y)5.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
EPS Next Y12.5%
EPS Next 2Y15.69%
EPS Next 3Y18%
EPS Next 5Y15.88%
Revenue 1Y (TTM)50.07%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%42.76%
Revenue Next Year46.32%
Revenue Next 2Y37.63%
Revenue Next 3Y33.25%
Revenue Next 5Y26.01%
EBIT growth 1Y13.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.23%
EBIT Next 3Y32.28%
EBIT Next 5Y29.2%
FCF growth 1Y36.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.44%
OCF growth 3YN/A
OCF growth 5YN/A

PROCEPT BIOROBOTICS CORP / PRCT FAQ

What is the fundamental rating for PRCT stock?

ChartMill assigns a fundamental rating of 4 / 10 to PRCT.


What is the valuation status for PRCT stock?

ChartMill assigns a valuation rating of 0 / 10 to PROCEPT BIOROBOTICS CORP (PRCT). This can be considered as Overvalued.


What is the profitability of PRCT stock?

PROCEPT BIOROBOTICS CORP (PRCT) has a profitability rating of 2 / 10.


What is the financial health of PROCEPT BIOROBOTICS CORP (PRCT) stock?

The financial health rating of PROCEPT BIOROBOTICS CORP (PRCT) is 6 / 10.